Stocks Health care VKTX
NASDAQ · Health careViking Therapeutics, Inc. (VKTX)
Viking Therapeutics, Inc. brought in $0 of revenue over the twelve months to September 30, 2026. It posted a net loss of $627.2M. At September 30, 2026 it held $677.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 29, 2026.
Key facts about Viking Therapeutics, Inc.
- Net worth
- Viking Therapeutics, Inc. has a market value (market cap) of $3.4B at the latest share price, and shareholders' equity of $588.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $0, with a net loss of $359.6M. Over the 12 months to September 30, 2026: revenue $0, net loss $627.2M.
- Cash flow
- In fiscal 2025 operations used $278.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 29, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Viking Therapeutics, Inc.'s next report is expected around February 10, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Viking Therapeutics, Inc. does
Viking Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker VKTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$359.6M | -$3.19 | n/a |
| 2024 | $0 | -$110M | -$1.01 | n/a |
| 2023 | $0 | -$85.9M | -$0.91 | n/a |
| 2022 | $0 | -$68.9M | -$0.90 | n/a |
| 2021 | $0 | -$55M | -$0.71 | n/a |
| 2020 | $0 | -$39.5M | -$0.54 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Viking Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- October 29, 2026
- October 28, 2026
- September 28, 2026Material agreement8-KViking Therapeutics closed an equity offering and a convertible senior notes offering to raise capital for clinical programs.
- September 24, 2026Form 305B2 filing 305B2
- September 22, 2026Other event 8-K
- July 30, 2026
- July 29, 2026
- July 29, 2026
- May 26, 2026
Insider trades
What the people running Viking Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 1, 2026 | Kelly-Gemmell Dorothy ElizabethDirector | Received as pay | 6,333 | - |
| July 29, 2026 | Mancini MariannaChief Operating Officer | Sold | 18,217 | $609.6K |
| July 29, 2026 | Zante GregChief Financial Officer | Sold | 21,217 | $710.1K |
| July 29, 2026 | Lian BrianPresident & CEO, Director | Sold | 148,517 | $4.9M |
| July 28, 2026 | Mancini MariannaChief Operating Officer | Received as pay | 31,667 | - |
| July 28, 2026 | Zante GregChief Financial Officer | Received as pay | 31,667 | - |
| July 28, 2026 | Lian BrianPresident & CEO, Director | Received as pay | 221,667 | - |
| March 10, 2026 | Aubuchon Neil WilliamChief Commercial Officer | Bought | 4,475 | $149.9K |
Who owns VKTX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 5.1% | November 5, 2025 |
| Vanguard Capital Management13G, passive | 5.08% | April 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 434 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 6,335,756 | +311,003 |
| BlackRock, Inc. | 6,189,649 | -690,641 |
| State Street Corp | 5,606,394 | +1,210,837 |
| Vanguard Capital Management LLC | 5,053,663 | +41,161 |
| Vanguard Portfolio Management LLC | 4,484,263 | +19,965 |
| Two Sigma Investments, LP | 3,937,414 | -494,728 |
| Morgan Stanley | 3,486,040 | +472,112 |
| Ameriprise Financial Inc | 2,156,083 | +477,338 |
| Geode Capital Management, LLC | 2,097,981 | +15,914 |
| American Century Companies Inc | 1,816,050 | -262,527 |
| D. E. Shaw & Co., Inc. | 1,605,994 | -70,719 |
| Bnp Paribas Financial Markets | 981,700 | +441,201 |
| Citadel Advisors LLC | 951,515 | -310,706 |
| Goldman Sachs Group Inc | 942,841 | -17,729 |
| UBS Group AG | 936,055 | -411,417 |
| Jpmorgan Chase & Co | 915,185 | +429,482 |
| Jane Street Group, LLC | 899,558 | +150,609 |
| Susquehanna International Group, Llp | 816,367 | +110,558 |
| Raymond James Financial Inc | 794,660 | -1,280,743 |
| Vanguard Fiduciary Trust Co | 732,047 | +21,635 |
Insiders
10 insiders reported holding 3,454,704 shares in total, about $100.2M at the last price.
| Holder | Shares |
|---|---|
| Lian BrianPresident & CEO, Director | 2,572,441 |
| Mancini MariannaChief Operating Officer | 422,760 |
| Zante GregChief Financial Officer | 212,204 |
| Foehr Matthew WDirector | 135,186 |
| Macartney LawsonDirector | 51,115 |
| Rowland Charles A JrDirector | 33,150 |
| Singleton J MatthewDirector | 12,650 |
| Kelly-Gemmell Dorothy ElizabethDirector | 6,333 |
| Aubuchon Neil WilliamChief Commercial Officer | 4,475 |
| Rouan Sarah KathrynDirector | 4,390 |
Questions about VKTX
What does Viking Therapeutics, Inc. do?
Viking Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as VKTX. Its shares trade on NASDAQ under the ticker VKTX.
What is Viking Therapeutics, Inc.'s net worth?
Viking Therapeutics, Inc. has a market value (market cap) of $3.4B at the latest share price, and shareholders' equity of $588.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Viking Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $627.2M.
How much revenue does Viking Therapeutics, Inc. make?
Over the twelve months to September 30, 2026 Viking Therapeutics, Inc. reported revenue of $0.
When did Viking Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 29, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the passive stake changed from November 5, 2026.
When is Viking Therapeutics, Inc.'s next earnings report?
Viking Therapeutics, Inc.'s next report is expected around February 10, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare VKTX with
Follow VKTX
Get an email when Viking Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Viking Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.